Efficacy and Safety of Rezivertinib in Locally Advanced or Metastatic/Recurrent EGFR T790M–Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M mutated NSCLC: a phase IIb study
J Thorac Oncol 2022 Aug 29;[EPub Ahead of Print], Y Shi, S Wu, K Wang, S Cang, W Yao, Y Fan, L Wu, M Huang, X Li, Y Pan, Z Yang, B Zhu, G Chen, J Shi, M Sun, J Fang, L Wang, Z Chen, C Liu, J Li, J Liu, S Sun, Y Zhao, Y Guo, Z Meng, Z Liu, Z Han, H Lu, R Ma, S Hu, G Zhao, Z Liu, C Xie, D Zhong, H Zhao, H Yu, L Zhang, M Bi, S Yi, S Guo, T Yi, W Li, Y Lin, Y Shu, Z Chen, Z Guo, M Greco, T Wang, H ShenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.